UK Government caught out lying about the cannabis plant, again.
It is simply miraculous that GW Pharmaceuticals can make an expensive spray form of whole cannabis plant extract simply by dissolving the plant in alcohol and adding some flavour, when the plant itself in the UK is scheduled as having no medicinal uses.
Secondly it is sad that cannabis grown in the UK has no medicinal value yet in Holland the plant grown there has a medicinal value when grown by a pharmaceutical company, Bedrocan is irradiated and standardised cannabis bud.
In the US they have been giving cannabis joints for medicinal use to a small number of people for DECADES so why do they do that if they at teh same time also deny the medicinal properties.
Thirdly, until 1971, cannabis tincture was prescribed; in his herbal book Culpeper listed some medicinal uses and it has been known that it was used in ancient Egypt and China as a medicine, and Queen Victoria herself used the plant as a medicine.
So what had happened to make cannabis in the UK so useless as a medicine since 1971? Is there something wrong with our air or water or sunlight or soils?
The only change is in the law, of course, so the law no favours pharmaceutical companies that hold us to ransom by charging such high prices for their Sativex?
The Government says Sativex is available on prescription but it is actually available only to a few that can persuade their doctors and then many have to pay - so that is a blatant distortion of truth again.
There are countless reports from people that suffer terrifying ailments and find ease or even cures from the cannabis plant itself and it was that anecdotal evidence that led GW Pharmaceuticals to invest in and study the plant and its medicinal uses that the Government denies.
There is only one word to describe the Government response - LIARS!
Herbal cannabis is listed in Schedule 1 as a drug with no
recognised medicinal uses outside research. A substantial body of
scientific evidence shows it is harmful and can damage human health.
The Government will not encourage the use of a Schedule 1 controlled
drug based on anecdotal evidence. It is important that a medicine is
very thoroughly trialled to ensure it meets rigorous standards before
being licensed and placed on the market so that doctors and patients are
sure of its efficacy and safety.
Cannabis in its raw form
(herbal cannabis) is not recognised as having any medicinal purposes in
the UK. There is already a clear regime in place to enable medicines
(including those containing controlled drugs) to be developed and
subsequently prescribed and supplied to patients via healthcare
professionals. This regime is administered by the Medicines and
Healthcare products Regulatory Agency (MHRA), which issues Marketing
Authorisations for drugs that have been tried and tested for their
safety and efficacy as medicines in the UK.
It is up to
organisations to apply for Marketing Authorisation for products that
they believe have potential medicinal purposes so that these can be
subject to the same stringent regime and requirements that all medicines
in the UK are subjected to.
Since 2010 UK patients can use the
cannabis-based medicine ‘Sativex’ for the treatment of spasticity due to
multiple sclerosis. ‘Sativex’ can also be prescribed for other
conditions at the prescribing doctor’s risk. ‘Sativex’ was rigorously
tested for its safety and efficacy before receiving approval, and is
distinguished from cannabis in its raw form. It is a spray which is
standardised in composition, formulation and dose and developed to
provide medicinal benefits without a psychoactive effect. Due to its low
psychoactive profile ‘Sativex’ was rescheduled from Schedule 1 and
placed in Schedule 4 Part 1 to enable its availability for use in
healthcare in the UK.
The MHRA is open to considering marketing
approval applications for other medicinal cannabis products should a
product be developed. As happened in the case of ‘Sativex’, the Home
Office will also consider issuing a licence to enable trials of new
medicines to take place under the appropriate ethical approvals.
In view of the potential harms associated with the use of cannabis in
its raw form and the availability of avenues for medicinal development,
the Government does not consider it appropriate to make changes to the
control status of raw or herbal cannabis.
The Government’s view
is that the Misuse of Drugs Act 1971 and regulations made under the Act
continue to facilitate the development of medicines which are made from
Schedule 1 controlled drugs. The legislation is aimed at protecting the
public from the potential harms of drugs and is not an impediment to
research into these drugs or development of medicines.
the Home Office undertook a scoping exercise targeted at a cross-section
of the scientific community, including the main research bodies, in
response to concerns from a limited number of research professionals
that Schedule 1 status was generally impeding research into new drugs.
Our analysis of the responses confirmed a high level of interest, both
generally and at institution level, in Schedule 1 research. However, the
responses did not support the view that Schedule 1 controlled drug
status impedes research in this area. While the responses confirmed Home
Office licensing costs and requirements form part of a number of issues
which influence decisions to undertake research in this area, ethics
approval was identified as the key consideration, while the next most
important consideration was the availability of funding.